Cervical cancer remains the most common gynaecologic malignancy in the world ([@bib6]). In 2008, nearly 530 000 women were diagnosed with cervical cancer and ∼275 000 died from this disease, which makes it the most deadly gynaecologic malignancy globally ([@bib6]). Cervical cancer is clinically staged, and the majority of early-stage cervical cancer patients who underwent surgical treatment with radical hysterectomy will receive postoperative adjuvant therapy based on the results of surgical--pathological risk factors ([@bib25]).

Histologically, surgical--pathological risk factors were classified into low-, intermediate-, and high-risk ([@bib3]; [@bib22]; [@bib19]). Positive lymph nodes, positive surgical margins, and parametrial involvement are classified as high-risk factors ([@bib19]), while large tumour size, lymphovascular space invasion (LVSI), and deep cervical stromal invasion are categorised as intermediate-risk factors ([@bib3]; [@bib22]). These risk factors are not only valuable to identify the patients who require postoperative adjuvant therapy, but are also important determinants of patient survival outcomes ([@bib5]). One of the limitations of this traditional risk factor classification is that the impact of multiple risk factors on survival outcomes remains not yet completely elucidated ([@bib16]; [@bib21]). Tumours may exhibit more than two risk factors with multiple high-risk factors or with combined intermediate- and high-risk factors. Therefore, profiling the significance of multiple risk factors quantitatively (by number of risk factors) and qualitatively (by magnitude of significance for survival) will help clinicians to guide the understanding of postoperative management of patients.

The aim of the study was to evaluate the survival outcomes of surgically treated early-stage cervical cancer patients by surgical--pathological risk factors examining the effects of number and hazard ratio (HR) for survival. Its utility of scoring was further examined to assess the treatment response of postoperative adjuvant therapy.

Material and methods
====================

Clinical information
--------------------

After the approval from Institutional Review Board was obtained at Osaka University Hospital and Osaka Medical Centre for Cancer and Cardiovascular Diseases, the institutional database from our Tumour Registry for cervical cancer was utilised to identify the cases. The inclusion criterion was having undergone radical hysterectomy and bilateral pelvic lymphadenectomy for stage IA2-IIB cervical cancer from January 1998 to December 2008. Cases with adenoid basal carcinoma, adenoid cystic carcinoma, glassy cell carcinoma, undifferentiated carcinoma, and small cell carcinoma were not included in the study. In our institutions, the histological evaluation of surgical specimens was performed by two independent gynaecologic pathologists based on the World Health Organisation ([@bib26]) staging system for tumours of the uterine cervix, and histology, LVSI, tumour size (largest diameter), marginal status (positive or negative for malignancy), parametrial involvement, deep stromal invasion (\>50%), and lymph nodal metastasis were routinely recorded. In our standard practice, cervical cancer was clinically staged according to the International Federation of Gynaecology and Obstetrics (FIGO) staging criteria. The initial work-up at the diagnosis consisted of: history taking for medico-surgical complication; complete physical examination; a complete blood count; chemistry panels; chest X-rays; computed tomography (CT) scans of the abdomen and pelvis; pelvic magnetic resonance imaging; and optional intravenous pyelography, cystoscopy, and recto-sigmoidoscopy. Para-aortic lymph nodes (PALN) were preoperatively evaluated with a CT scan of the abdomen as part of the routine initial evaluation. Subsets of the patients evaluated in the study were within the context of previous clinical studies ([@bib12], [@bib13], [@bib14]; [@bib18]).

Treatments
----------

### Surgery

All patients were treated with type III radical hysterectomy and pelvic lymphadenectomy, as reported previously ([@bib13]). Lymphadenectomy included complete bilateral pelvic lymphadenectomy aiming the removal of all of external iliac, internal iliac, common iliac, obturator, suprainguinal, and presacral lymph nodes systematically. Intra-operative assessment of the PALN was routinely performed by manual palpation. When PALN metastasis was preoperatively or intraoperatively suspected, nodal resection was performed for histological confirmation. Cases with histologically confirmed PALN metastasis were not included in the study.

### Postoperative radiotherapy

Postoperative radiotherapy is indicated when patient\'s pathological report displays any of the following 'high-risk\' prognostic factors: parametrial invasion, pelvic lymph node metastasis, or a positive surgical margin, or one of the following 'intermediate-risk\' prognostic factors: deep stromal invasion, LVSI, or a large tumour (over 4 cm in diameter). A group of cases with early-stage cervical cancer without any of the above-mentioned risk factors and who, therefore, did not receive postoperative adjuvant therapy was categorised as low-risk group. These low-, intermediate-, and high-risk factors were termed as 'traditional risk factor\' in the study.

In our standard radiotherapy, patients receive external beam pelvic radiotherapy plus concurrent chemoradiotherapy (CCRT), as reported previously ([@bib12], [@bib13], [@bib14]). However, historically, patients who received a care before January 1999 in our practice were treated with pelvic radiotherapy alone. Patients who declined CCRT also received radiotherapy alone. Postoperative whole-pelvic radiotherapy was performed using 10 megavolt (MV) X-rays delivered from a linear accelerator using the antero-posterior parallel opposing technique. The superior margin of the external radiation field was located at the top of the fifth lumber vertebra, and the inferior border of the obturator foramen was used as the distal margin. Laterally, the field extended 2 cm beyond the lateral margin of the bony pelvic wall. We used multi-leaf collimators to block the upper and lower corners of the radiation field. The external irradiation was delivered to the whole pelvis at 2 Gy per fraction in five fractions per week for a total of 25 fractions (total dose, 50 Gy).

Among patients for whom CCRT was initially planned, 26 patients whose pathological reports revealed multiple pelvic node metastases were treated with extended field radiotherapy (EFRT) without CCRT, as reported previously ([@bib14]). Postoperative EFRT was also administered to the patients via 10 MV X-rays delivered from a linear accelerator using the antero-posterior parallel opposing technique. The radiation field encompassed the pelvic and the PALN drainage area. The superior margin of the PALN area was located at the bottom of the T12 vertebral body, and the inferior margin was located at the inferior border of the obturator foramen. The lateral margin was located at 1.5--2 cm lateral to the widest point of the bony pelvis. The external irradiation was delivered to the EFRT fields for a total of 45 Gy in 25 fractions and to the whole pelvis at 1.8 Gy per fraction for a total of 28 fractions (total dose, 50.4 Gy).

### Concurrent chemoradiotherapy

In our institutions, nedaplatin is administered as the radiosensitising agent for patients with cervical cancer. Nedaplatin was given intravenously during the course of radiotherapy, as reported previously ([@bib12]; [@bib11]; [@bib14]).

### Follow-up

The patients were followed regularly both by gynaecological oncologists and radiation oncologists after treatment, as described previously ([@bib10], [@bib9]). When recurrence was clinically or radiographically suspected, a biopsy was performed for confirmation whenever possible. The median follow-up duration was 5.0 years (range 0.5--5.1).

Statistical analysis
--------------------

We first determined the statistical significance of surgical--pathological risk factors associated with survival outcomes both for disease-free survival (DFS) and for overall survival (OS). Then, three scoring methods were examined to evaluate the predictive value for recurrence or disease-related death in receiver-operator-characteristic curve analysis comparing area-under-curve (AUC). The first scoring method recorded the crude number of risk factors per individual (Number method). For instance, if the patient had two risk factors, the score is recorded as 2 for the case. The remaining two methods were based on weighting the value of HR determined in multivariate analysis: (i) entering all surgical--pathological risk factors that showed statistical significance in univariate analysis (Risk-weighted method 1); (ii) and entering only those statistically significant surgical--pathological risk factors that were demonstrated in the conditional backward method (Risk-weighted method 2). For instance, if the patient has two risk factors (HR 3.2 for one risk factor and HR 2.4 for the other risk factor), the score will be 3.2+2.4=5.6 for the case. In addition to these three methods, traditional risk factor method (low, intermediate, and high) and clinical staging method (IA2-IIB) were also examined for the predictive value for survival outcomes. Among the three methods proposed in the current study, the scoring method with the highest AUC for survival events was chosen for the further analysis. To implicate the utility of scoring method in clinical practice, the survival outcomes, as well as treatment response for postoperative adjuvant therapy, were examined based on the scoring results. Survival curves were constructed using the Kaplan--Meier method, and the significance of survival differences was determined with the log-rank test in univariate analysis. For multivariate analysis, Cox proportional-hazards regression test was performed to assess the ability of the prognostic factors to predict survival outcomes expressed as HR and 95% confidence interval (CI). Fisher\'s exact test was used for categorical variables expressed with odds ratio (OR) with 95% CI. Ordinal variables were examined for the statistical significance using Spearman\'s correlation coefficient. All statistical analyses were two-tailed, and *P*-values of \<0.05 were considered statistically significant. Statistical Package for Social Scientists software (SPSS, version 12.0, IL, USA) was used for all analyses.

Results
=======

Patient characteristics
-----------------------

There were 540 cases evaluated for the analysis. The clinico-pathological demographics of patients are shown in [Table 1](#tbl1){ref-type="table"}. In our study, LVSI (58.3%) and deep stromal invasion (49.3%) were the common risk factors, and positive margins were relatively infrequent. The surgical--pathological risk factors were correlated for statistical significance ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). All the traditional risk factors had either significant or marginal correlations with each other. Among the significant correlations, LVSI and pelvic nodal metastasis showed the strongest correlation (41.9% *vs* 0.4%, OR 162, 95% CI 22.3--1167, *P*\<0.001). None of low-risk factor patients (43.1%) received postoperative therapy. Among intermediate- or high-risk patients (*n*=307), 188 (61.2%) patients received CCRT and the remaining 119 (38.8%) received radiotherapy alone. Ninety-seven (18.0%) cases developed recurrence and 69 (12.8%) cases died of disease.

Surgical--pathological risk factors and survival outcomes
---------------------------------------------------------

Seven pathological factors were then correlated to DFS and OS ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). Univariate analysis identified all of these seven pathological factors as statistically significant variables for both DFS and OS. In multivariate analysis where all seven pathological factors were entered, the magnitudes of significance for DFS were in the following order: LVSI (HR 3.95), nodal metastasis (HR 3.88), non-squamous histology (HR 3.40), large tumour (HR 2.36), positive marginal status (HR 1.99), deep stromal invasion (HR 1.29), and parametrial invasion (HR 1.21) (Multivariate 1 method in [Table 2](#tbl2){ref-type="table"}). Multivariate analysis in conditional backward method showed majority of variables to be significant for DFS (Multivariate 2 in [Table 2](#tbl2){ref-type="table"}).

Similarly, 5-year OS rates were examined ([Table 3](#tbl3){ref-type="table"}): in multivariate analysis where all seven pathological factors were entered, the magnitudes of significance for OS were in the following order: LVSI (HR 6.02), nodal metastasis (HR 3.61), non-squamous histology (HR 3.48), positive marginal status (HR 2.09), large tumour (HR 1.31), deep stromal invasion (HR 1.30), and parametrial invasion (HR 1.02) (Multivariate 1 method in [Table 3](#tbl3){ref-type="table"}). In multivariate analysis using conditional backward method, LVSI (HR 7.28), nodal metastasis (HR 3.91), non-squamous histology (HR 3.38) remained as the three strongest independent risk factors associated with OS (Multivariate 2 method in [Table 3](#tbl3){ref-type="table"}).

Comparison of surgical--pathological risk factor scoring methods
----------------------------------------------------------------

Three systemic methods of scoring utilising the results of survival analysis were compared ([Table 4](#tbl4){ref-type="table"}). There were 425 (78.7%) of cases that showed at least one risk factor. In Number method, the median number of risk factors per case was 2. In Risk-weighted method 1, the mean value was 5.24 for DFS and 7.32 for OS, respectively. For Risk-weighted method 2, the mean value was 5.12 for DFS and 6.31 for OS, respectively. Frequencies of these three methods are shown in [Supplementary Figure S1A--E](#sup1){ref-type="supplementary-material"}. Area-under-curve was examined for predictive value for recurrence or death due to disease using these three scoring methods ([Table 4](#tbl4){ref-type="table"}). All three methods showed considerably high predictive values for survival events (AUC \>0.8 for all), and these values were higher than traditional pathological risk factor or clinical staging methods (both, AUC \<0.8). Among the tested methods, Risk-weighted method 1 showed the highest predictive value for both recurrence (AUC 0.836) and death due to disease (AUC 0.837). Therefore, this method was used for the further analysis in the study.

Risk-weighted surgical--pathological score was positively correlated to traditional pathological risk factor ([Figure 1A](#fig1){ref-type="fig"}) and clinical stage ([Figure 1B](#fig1){ref-type="fig"}). Survival curves were constructed based on the extent of score values ([Figures 1C and D](#fig1){ref-type="fig"}). Five-year DFS rate were 96.6%, 93.2%, 84.1%, 73.1%, 53.3%, and 23.8% for score 0, 1.0--4.9, 5.0--7.4, 7.5--9.9, 10.0--12.4, and ⩾12.5, respectively (*P*\<0.001, [Figure 1C](#fig1){ref-type="fig"}). Five-year OS rate were 100%, 94.9%, 88.9%, 79.0%, 71.9%, and 43.3% in these score groups, respectively (*P*\<0.001, [Figure 1C](#fig1){ref-type="fig"}). Magnitude of statistical significance in risk-weighted surgical--pathological scoring method was larger than traditional risk factor method in DFS with wider range of survival rates among groups (log-rank value, 154.3 *vs* 78.5; 5-year DFS range, 23.8--96.6% *vs* 58.5--94.4% [Figures 1C vs E](#fig1){ref-type="fig"}) and in OS (log-rank value, 119.2 *vs* 59.0; 5-year OS range, 43.3--100% *vs* 71.0--97.7% [Figures 1D vs 1F](#fig1){ref-type="fig"}). Similarly, magnitude of significance in risk-weighted surgical--pathological scoring method was larger than clinical staging method both in DFS (log-rank value, 154.3 *vs* 82.5; 5-year DFS range, 23.8--96.6% *vs* 53.9--89.7% [Figures 1C vs G](#fig1){ref-type="fig"}) and in OS (log-rank value, 119.2 *vs* 51.6; 5-year OS range, 43.3--100% *vs* 68.1--100% [Figures 1D vs H](#fig1){ref-type="fig"}). Number method showed similar results to the risk-weighted surgical--pathological methods ([Supplementary Figures S2A--B](#sup1){ref-type="supplementary-material"}).

Risk-weighted surgical--pathological scoring and treatment response
-------------------------------------------------------------------

Clinical implications of risk-weighted surgical--pathological factor scoring were examined among patients that proceeded to receive postoperative adjuvant therapy (*n*=307). Five-year DFS rate was evaluated between CCRT and radiotherapy (RT) alone groups based on the scoring value ([Figures 2A--F](#fig2){ref-type="fig"}): score 0, no patient received adjuvant therapy ([Figure 2A](#fig2){ref-type="fig"}); score 1.0--4.9, 100% *vs* 81.0% (*P*=0.025, [Figure 2B](#fig2){ref-type="fig"}); score 5.0--7.4, 91.4% *vs* 68.2% (*P*=0.006, [Figure 2C](#fig2){ref-type="fig"}); score 7.5--9.9, 82.4% *vs* 56.1% (*P*=0.024, [Figure 2D](#fig2){ref-type="fig"}); score 10--12.4, 58.8% *vs* 46.2% (*P*=0.16, [Figure 2E](#fig2){ref-type="fig"}), and score ⩾12.5, 20.0% *vs* 25.6% (*P*=1.0, [Figure 2F](#fig2){ref-type="fig"}). Risk-weighted surgical--pathological score was statistically significantly correlated with the magnitude of HR for CCRT in DFS (Spearman\'s *r*=1.0, *P*\<0.001, [Figure 2G](#fig2){ref-type="fig"}), implying that higher scores in the method offset the clinical benefits of CCRT when compared with RT alone. Similar results were seen in OS although it did not reach statistical significance (*r*=0.7, *P*=0.19, [Figure 2H](#fig2){ref-type="fig"}). This finding was not picked up by the traditional risk factor classification, and when the high-risk group patients were examined for DFS (*n*=177), CCRT remained as the beneficial therapeutic modality when compared with RT alone (HR 0.43, *P*=0.001).

Multiple traditional risk factors and risk-weighted surgical--pathological scoring
----------------------------------------------------------------------------------

Tumour spread and metastasis patterns were examined based on the number and extent of high- and intermediate-risk factors. Surgical--pathological risk factor array is shown in [Table 5](#tbl5){ref-type="table"}. There were 44 total patterns of tumour spread in cervical cancer, and 29 (65.9%) patterns fell into high-risk groups in traditional risk classification. Of those, 12 (41.4%) patterns representing 68 (12.6%) patients demonstrated multiple high-risk factors, and 22 (75.9%) showed a high-risk factor with ⩾2 intermediate-risk factors (148 patients, 27.4%). Among the 15 (34.1%) patterns included in the traditional intermediate-risk group, 8 (53.3%) patterns accounted for 98 (18.1%) patients that exhibited two or greater intermediate-risk factors.

Among the 44 patterns of tumour spread, 18 (40.9%) patterns showed risk-weighted surgical--pathological score of ⩾10. Of those, LVSI (100%), nodal metastasis (83.3%), and deep stromal invasion (83.3%) were the three most common risk factors. Among the 18 patterns with a risk-weighted surgical--pathological score of ⩾10, 17 (94.4%) patterns had at least two risk factors (high and/or intermediate) with two high- and two intermediate-risk factors being the most common pattern (four patterns, *n*=35), followed by two high- and three intermediate-risk factors (3 patterns, *n*=28). Neither of the two risk factor patterns showed a survival benefit with additional platinum-based chemotherapy and radiotherapy over radiotherapy alone (5-year DFS rate in CCRT *vs* RT alone, two high- and two intermediate-risk groups, 44.6% *vs* 50.0%, *P*=0.81; and two high- and three intermediate-risk groups, 53.7% *vs* 50.7%, *P*=0.73).

Discussion
==========

The important findings of our study were that when early-stage cervical cancer was classified based on the extent of risk factors weighting its magnitude of significance, we were able to identify the subgroup of patients with survival outcomes comparable to advanced-stage disease. Furthermore, benefits of CCRT over RT alone among surgically treated early-stage cervical cancer showed a trend towards diminishing as the tumour expresses its aggressiveness. Several key areas in this observation deserve special mention.

In our study, early FIGO stage cervical cancer patients with a surgical--pathological score \>10 have a similar survival outcomes compared with FIGO stage III patients. Overall, 5-year DFS of FIGO stage III cervical cancer is reported as 30--50% ([@bib25]). Patients with risk-weighted surgical--pathological score of 10--12.4 and ⩾12.5 showed 5-year DFS of 53.3% and 23.8%, respectively. In addition, 5-year OS of FIGO stage III disease is 39.7--41.5% in general population that is similar to the patients with score of ⩾12.5 in our study population (43.3%) ([@bib20]). Our scoring method was not only correlated well to the traditional classification ([Figures 1A and B](#fig1){ref-type="fig"}), but also demonstrated wider ranges of survival difference among the early-stage cervical cancer patients ([Figures 1C--H](#fig1){ref-type="fig"}). These findings support the usefulness and durability of risk-weighted surgical--pathological scoring to enable the clinician to recognise that there is a certain population of early-stage cervical cancer patients with considerably poor survival outcomes, proposed as 'super high-risk\' group for cervical cancer in our study (score ⩾12.5). Risk factors examined in our scoring method were similar to traditional scoring system except for histology type. Our results indicated that adenocarcinoma and adenosquamous histology remained as an independent risk factor for survival exhibiting one of the largest significances both for DFS and OS ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). As the pathophysiology and optimal management of adenocarcinoma of the cervix is not yet well understood, additional studies are warranted by others to reproduce our results ([@bib4]).

Surprisingly, the larger the risk-weighted surgical--pathological score was, the lower the benefit of additional platinum-based chemotherapy during radiotherapy after radical hysterectomy was ([Figures 2G--H](#fig2){ref-type="fig"}). This finding was clearly evident in the group with scores greater than 10. It is speculated that these patients with score ⩾10 likely have occult distant metastases that could not be sterilised by additional platinum-based chemotherapy. As the concurrent administration of cisplatin-based chemotherapy during radiotherapy is a standard practice for postoperative adjuvant therapy (high-risk or intermediate-risk groups), additional therapeutic approaches are needed to improve the survival outcome in this particular population of 'super high-risk\' group. Lymphovascular space invasion, adenocarcinoma or adenosquamous, and lymph nodal metastasis were the top three risk factors with large HR associated with decreased DFS and OS in our study. Therefore, targeting these risk factors will be an attractive therapeutic approach. Recent studies have demonstrated that increased LVSI is strongly associated with vascular endothelial growth factor (VEGF) pathway in solid tumours ([@bib8]; [@bib23]; [@bib1]). In addition, LVSI is significantly correlated with nodal metastasis ([@bib7]; [@bib15]). Therefore, it may be reasonable to consider administering anti-VEGF agents to 'super high-risk\' tumours exhibiting LVSI ([@bib17]). In a recent review, providing additional paclitaxel to treatment, extending the chemotherapy course, and selecting a biological target such as anti-VEGF or anti-epidermal growth factor receptor agents are suggested to have a potential role in the management of adenocarcinoma of the cervix ([@bib4]). Finally, as the survival outcomes of patients with risk-weighted surgical score ⩾12.5 is similar to advanced-stage disease, the indication and efficacy of consolidation therapy after postoperative adjuvant treatment needs to be considered in the future ([@bib24]; [@bib27]; [@bib2]).

The role of multiple risk factors in risk-weighted surgical--pathological scoring merits further discussion. In a review of literature, analyses of pooled data from GOG/SWOG/RTOG trials evaluating tumours with high-risk factors based on the presence of additional intermediate-risk factors (tumour size) showed that adding platinum-based chemotherapy to radiotherapy after radical hysterectomy for stage IA2-IIA cervical cancer significantly improved survival outcome if the tumour was \>2 cm (5-year survival rate, 19% absolute improvement) ([@bib16]). In addition, the results of a phase III randomised trial that enrolled node-negative stage IB cervical cancer patients exhibiting multiple intermediate-risk factors showed that pelvic radiotherapy after radical hysterectomy significantly reduced risk of recurrence when compared with the treatment arm without additional radiotherapy ([@bib21]). In our results shown in [Table 5](#tbl5){ref-type="table"}, a considerable proportion of cervical cancer patients exhibited multiple high-risk factors (12.6%) or high-risk factor with multiple intermediate-risk factors (27.4%), and these multiple high-risk factor tumours did not show benefits of CCRT over RT alone. As cervical cancer patients with multiple high-risk factors are not rare and such patients have not yet been fully evaluated for the role of additional platinum-based chemotherapy with radiotherapy, further prospective cohort studies are merited.

The strength of our study is that the sample size is adequate for the analysis and that treatment plan and pathology evaluation are similar between the two institutions that participated in the study. A potential weakness of the study is that it is retrospective in nature, and thus factors such as treatment algorithms, including various surgical techniques, chemotherapy protocols, and radiation approaches, may be confounded. Another limitation is that we do not have data for how patients were allocated to treatment types (selection bias).

In conclusion, evaluation of surgically treated cervical cancer by number of tumour risk factors with its magnitude of significance for survival demonstrated the ability to understand the aggressiveness of tumour biology. This approach merits further investigation especially in its implication to postoperative adjuvant therapy.
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![**Risk-weighted surgical--pathological scoring and survival outcome.** (**A--B**) Spearman\'s correlation coefficient between surgical--pathological scoring value (based on HR in multivariate analysis all the risk factors were entered) and (**A**) traditional pathological risk factor (in order of low, intermediate, and high) and (**B**) clinical stage (in order of IA2, IB1, IB2, IIA, and IIB). (**C, D**) Survival curves based on risk-weighted surgical--pathological scoring value (method 1). (**E, F**) Survival curves based on traditional surgical--pathological risk factor. (**G, H**) Survival curves based on clinical stage. Kaplan--Meier method for survival curves expressed with log-rank statistics and *P*-value.](bjc201378f1){#fig1}

![**Surgical--pathological scoring and postoperative therapy response.** (**A--F**) Kaplan--Meier survival curves based on risk-weighted surgical--pathological scoring value (method 1) were examined for the type of postoperative adjuvant therapy after radical hysterectomy (CCRT (black line) and RT alone (dash line)). *P-*value for log-rank test. (**G, H**) Spearman\'s correlation coefficient between risk-weighted surgical--pathological scoring value (method 1) and HR for CCRT in (**G**) DFS and (**H**) OS. Hazard ratio towards 0 implies benefits of CCRT over RT alone while HR towards 1 implies no benefit of CCRT over RT alone on survival outcomes.](bjc201378f2){#fig2}

###### Patient demographics

  **Subjects**                                        ***N*****=540**
  --------------------------------------------------- -----------------
  Age                                                 47 (±11.2)
  **Clinical stage^b^**                               
   IA2                                                35 (6.5%)
   IB1                                                312 (57.8%)
   IB2                                                48 (8.9%)
   IIA                                                65 (12.0%)
   IIB                                                80 (14.8%)
  **Histology**                                       
   Squamous                                           377 (69.8%)
   Adenocarcinoma                                     143 (26.5%)
   Adenosquamous                                      20 (3.7%)
  **High-risk factors**                               
   Lymph node metastasis                              133 (24.6%)
   Parametria invasion                                103 (19.1%)
   Positive marginal status                           19 (3.5%)
  **Intermediate-risk factors**                       
   LVSI                                               315 (58.3%)
   Deep stromal invasion                              266 (49.3%)
   Large tumour (\>4 cm)[a](#t1-fn3){ref-type="fn"}   100 (18.5%)
  **Postoperative adjuvant therapy**                  
   None                                               233 (43.1%)
   CCRT                                               188 (34.8%)
   RT alone                                           119 (22.0%)
  **Pathological risk group**                         
   Low                                                233 (43.1%)
   Intermediate                                       130 (24.1%)
   High                                               177 (32.8%)

Abbreviations: CCRT=concurrent chemoradiotherapy; LVSI=lymphovascular space invasion; RT=radiotherapy.

Mean (±s.d.), median (range), or number (%) is shown.

Median tumour size is 3.0 cm (range 0.5--8.0 cm).

As per the International Federation of Gynaecology and Obstetrics (FIGO) staging criteria.

###### Disease-free survival based on surgical--pathological factors

                                  **Univariate**      **Multivariate 1**   **Multivariate 2**                                 
  ----------------------- ------- ------------------- -------------------- -------------------- --------- ------------------- ---------
  Histology                                           0.004                                     \<0.001                       \<0.001
   SCC                    81.9%   1                                        1                              1                    
   AC/ AS                 72.0%   1.79 (1.20--2.68)                        3.40 (2.23--5.20)              3.36 (2.20--5.14)    
  Lymph node metastasis                               \<0.001                                   \<0.001                       \<0.001
   No                     89.6%   1                                        1                              1                    
   Yes                    49.4%   6.54 (4.33--9.89)                        3.88 (2.41--6.24)              4.19 (2.64--6.65)    
  Parametria invasion                                 \<0.001                                   0.41                           
   No                     84.1%   1                                        1                                                   
   Yes                    58.7%   3.30 (2.20--4.95)                        1.21 (0.77--1.92)                                   
  Marginal status                                     \<0.001                                   0.05                          0.031
   Negative               80.1%   1                                        1                              1                    
   Positive               50.0%   4.19 (2.18--8.07)                        1.99 (1.00--3.95)              2.11 (1.07--4.17)    
  LVSI                                                \<0.001                                   \<0.001                       \<0.001
   No                     95.5%   1                                        1                              1                    
   Yes                    67.9%   9.08 (4.41--18.7)                        3.95 (1.71--9.14)              4.62 (2.09--10.2)    
  Deep stromal invasion                               \<0.001                                   0.4                            
   No                     91.1%   1                                        1                                                   
   Yes                    67.4%   4.47 (2.73--7.30)                        1.29 (0.71--2.35)                                   
  Large tumour                                        \<0.001                                   0.06                          0.025
   No                     82.9%   1                                        1                              1                    
   Yes                    62.3%   2.76 (1.82--4.20)                        2.36 (0.98--2.36)              1.64 (1.06--2.52)    

Abbreviations: AC=adenocarcinoma; AS=adenosquamous; 95% CI=95% confidence interval; HR=hazard ratio; LVSI=lymphovascular space invasion; SCC=squamous cell carcinoma; 5-yr (%)=5-year disease-free survival rate.

Cox proportional-hazards regression test for multivariate 1 (with all variables entered) and multivariate 2 (conditional backward method). *P*-value for univariate, log-rank test.

###### Overall survival based on surgical--pathological factors

                                  **Univariate**      **Multivariate 1**   **Multivariate 2**                                 
  ----------------------- ------- ------------------- -------------------- -------------------- --------- ------------------- ---------
  Histology                                           0.005                                     \<0.001                       \<0.001
   SCC                    88.7%   1                                        1                              1                    
   AC/AS                  79.6%   1.95 (1.21--3.13)                        3.48 (2.11--5.74)              3.38 (2.06--5.54)    
  Lymph node metastasis                               \<0.001                                   \<0.001                       \<0.001
   No                     93.5%   1                                        1                              1                    
   Yes                    63.4%   6.70 (4.08--11.0)                        3.61 (2.11--5.74)              3.91 (2.28--6.70)    
  Parametria invasion                                 \<0.001                                   0.93                           
   No                     89.1%   1                                        1                                                   
   Yes                    72.9%   2.77 (1.70--4.51)                        1.02 (0.59--1.77)                                   
  Marginal status                                     \<0.001                                   0.07                          0.036
   Negative               86.7%   1                                        1                              1                    
   Positive               64.7%   4.06 (1.94--8.50)                        2.09 (0.94--4.64)              2.28 (1.06--4.93)    
  LVSI                                                \<0.001                                   \<0.001                       \<0.001
   No                     97.1%   1                                        1                              1                    
   Yes                    77.9%   12.8 (4.68--35.3)                        6.02 (1.95--18.6)              7.28 (2.49--21.3)    
  Deep stromal invasion                               \<0.001                                   0.48                           
   No                     94.3%   1                                        1                                                   
   Yes                    77.8%   4.79 (2.62--8.77)                        1.30 (0.63--2.67)                                   
  Large tumour                                        \<0.001                                   0.31                           
   No                     88.3%   1                                        1                                                   
   Yes                    75.4%   2.48 (1.51--4.07)                        1.31 (0.77--2.23)                                   

Abbreviations: AC=adenocarcinoma; AS=adenosquamous; 95% CI=95% confidence interval; HR=hazard ratio; LVSI=lymphovascular space invasion; SCC=squamous cell carcinoma; 5-yr (%)=5-year disease-free survival rate.

Cox proportional-hazards regression test for multivariate 1 (with all variables entered) and multivariate 2 (conditional backward method). *P*-value for univariate, log-rank test.

###### Comparison of scoring methods for survival outcomes

  **Score type**                **Number**                      **Risk-weighted 1**                     **Risk-weighted 2**                **Traditional**                 **Stage**
  ------------------- ------------------------------ ------------------------------------------ ------------------------------------ --------------------------- -----------------------------
  Method               Sum of number of risk factor   HR-weighted (with all variables entered)   HR-weighted (conditional backward)   Risk factor (L, I or H)\*   Clinical stage at diagnosis
  **Ordinal group**                                                                                                                                              
   1                          0 Risk factor                           Score 0                                 Score 0                            Low                       Stage IA2
   2                          1 Risk factor                        Score 1.0--4.9                          Score 1.0--4.9                   Intermediate                   Stage IB1
   3                          2 Risk factors                       Score 5.0--7.4                          Score 5.0--7.4                       High                       Stage IB2
   4                          3 Risk factors                       Score 7.5--9.9                          Score 7.5--9.9                                                  Stage IIA
   5                          4 Risk factors                       Score 10--12.4                          Score 10--12.4                                                  Stage IIB
   6                          5 Risk factors                         Score⩾12.5                              Score⩾12.5                                                         
   7                          6 Risk factors                                                                                                                                    
   8                          7 Risk factors                                                                                                                                    
  Score range                      0--6                      DFS 0--15.95, OS 0--17.53                 DFS 0--15.92, OS 16.85                                                   
  AUC for rec                     0.817                                0.836                                   0.822                            0.756                        0.747
  Range                        0.771--0.862                         0.791--0.882                            0.776--0.868                    0.705--0.807                 0.694--0.801
  P-value                       *P*\<0.001                           *P*\<0.001                              *P*\<0.001                      *P*\<0.001                   *P*\<0.001
  AUC for DOD                     0.816                                0.837                                   0.830                            0.769                        0.734
  Range                        0.772--0.861                         0.791--0.883                            0.779--0.880                    0.717--0.820                 0.673--0.796
  P-value                       *P*\<0.001                           *P*\<0.001                              *P*\<0.001                      *P*\<0.001                   *P*\<0.001

Abbreviations: AUC=area under the curve; DFS=disease-free survival; DOD=die of disease; H=high-risk; HR=hazard ratio; I=intermediate-risk; L=low-risk; rec=recurrence; OS=overall survival.

*P*-value for receiver-operator-characteristics curve analysis for predicting the events (recurrence or die of disease). Risk-weighted method 1, sum of HR(s) for presented risk factor(s) using the results of multivariate analysis in which all pathological risk factors were entered. Risk-weighted method 2, sum of HR(s) for presented risk factor(s) using the results of multivariate analysis in which only significant variables determined by the conditional backward method were entered.

###### Surgical--pathological risk factor array for risk of disease-free survival

   **Adeno (3.40)**   **Nodal mets (3.88)**   **Parametria (1.21)**   **Margin+ (1.99)**   **LVSI (3.95)**   **DSI (1.29)**   **Large tumour (2.36)**   **Risk group (traditional)**  **High risk (No.)**   **Intermediate risk (No.)**   **Subject no.**   **Surg-path score**
  ------------------ ----------------------- ----------------------- -------------------- ----------------- ---------------- ------------------------- ------------------------------ --------------------- ----------------------------- ----------------- ---------------------
          \+                   \+                      \+                     \+                 \+                                     \+                           H                3                     2                             1                 16.79
          \+                   \+                      \+                                        \+                \+                   \+                           H                2                     3                             3                 16.09
          \+                   \+                      \+                     \+                 \+                \+                                                H                3                     2                             2                 15.72
          \+                   \+                                                                \+                \+                   \+                           H                1                     3                             4                 14.88
                               \+                      \+                     \+                 \+                \+                   \+                           H                3                     3                             4                 14.68
          \+                   \+                      \+                                        \+                \+                                                H                2                     2                             7                 13.73
          \+                   \+                                                                \+                                     \+                           H                1                     2                             1                 13.59
                               \+                                             \+                 \+                \+                   \+                           H                2                     3                             1                 13.47
                               \+                      \+                                        \+                \+                   \+                           H                2                     3                             17                12.69
                               \+                      \+                     \+                 \+                \+                                                H                3                     2                             3                 12.32
          \+                                           \+                                        \+                \+                   \+                           H                1                     3                             4                 12.21
          \+                                           \+                     \+                 \+                \+                                                H                2                     2                             1                 11.84
                               \+                                                                \+                \+                   \+                           H                1                     3                             11                11.48
          \+                   \+                                                                \+                                                                  H                1                     1                             2                 11.23
                               \+                                             \+                 \+                \+                                                H                2                     2                             2                 11.11
          \+                                                                                     \+                \+                   \+                           I                0                     3                             3                 11.00
                               \+                      \+                                        \+                \+                                                H                2                     2                             25                10.33
                               \+                                                                \+                                     \+                           H                1                     2                             2                 10.19
          \+                                           \+                                        \+                \+                                                H                1                     2                             4                 9.85
          \+                                                                                     \+                                     \+                           I                0                     2                             1                 9.71
          \+                                                                  \+                 \+                                                                  H                1                     1                             1                 9.34
                               \+                                                                \+                \+                                                H                1                     2                             29                9.12
                               \+                                                                \+                \+                                                H                1                     2                             11                9.12
                                                       \+                                        \+                \+                   \+                           H                1                     3                             14                8.81
          \+                                                                                     \+                \+                                                I                0                     2                             26                8.64
                                                       \+                     \+                 \+                \+                                                H                2                     2                             2                 8.44
                               \+                                                                \+                                                                  H                1                     1                             9                 7.83
                                                                                                 \+                \+                   \+                           I                0                     3                             21                7.6
          \+                                                                                     \+                                                                  I                0                     1                             21                7.35
          \+                                                                                                       \+                   \+                           I                0                     2                             3                 7.05
                                                                                                 \+                                     \+                           I                0                     2                             4                 6.31
          \+                                           \+                                                          \+                                                H                1                     1                             2                 5.90
          \+                                                                                                                            \+                           I                0                     1                             1                 5.76
                                                                                                 \+                \+                                                I                0                     2                             37                5.24
                               \+                                                                                  \+                                                H                1                     1                             1                 5.17
          \+                                                                                                       \+                                                I                0                     1                             6                 4.69
                                                                              \+                                                        \+                           H                1                     1                             1                 4.35
                                                                                                 \+                                                                  I                0                     1                             42                3.95
                                                                                                                   \+                   \+                           I                0                     2                             3                 3.65
          \+                                                                                                                                                                          0                     0                             70                3.40
                                                       \+                                                          \+                                                H                1                     1                             3                 2.50
                                                                                                                                        \+                           I                0                     1                             1                 2.36
                                                                              \+                                                                                     H                1                     0                             1                 1.99
                                                                                                                   \+                                                I                0                     1                             18                1.29

Abbreviations: Adeno=adenocarcinoma/adenosquamous carcinoma; DSI=deep stromal invasion; H=high-risk; I=intermediate-risk; LVSI=lymphovascular space invasion; Margin+ =positive marginal status; Nodal mets=pelvic lymph node metastasis.

A total of 44 patterns of tumour spread/metastasis are shown in descending order of risk-weighted surgical--pathological score. In each row, corresponding risk factor(s) are listed. Risk group (traditional): presence of any of high-risk factor (H) or intermediate-risk factor without high-risk factor (I). High risk (no.) and Intermediate risk (no.): number of high-risk factors and intermediate-risk factors per each pattern of tumour spread/metastasis, respectively.

[^1]: These authors contributed equally to this study.
